Biomedical Engineering Reference
In-Depth Information
(DPDPE): pharmacokinetic consequences of the interplay between multiple transport
systems. J Pharmacol Exp Ther 311:1203-1210.
76. Zeilinger K, Sauer IM, Pless G, Strobel C, Rudzitis J, Wang A, Nussler AK, Grebe
A, Mao L, Auth SH, et al. 2002. Three-dimensional co-culture of primary human
liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on
the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim 30:525-
538.
77. Allen JW, Khetani SR, Bhatia SN. 2005. In vitro zonation and toxicity in a hepatocyte
bioreactor. Toxicol Sci 84:110-119.
78. de Kanter R, Monshouwer M, Meijer DK, Groothuis GM. 2002. Precision cut organ
slices as a tool to study toxicity and metabolism of xenobiotics with special reference to
non-hepatic tissues. Curr Drug Metab 3:39-59.
79. van de Bovenkamp M, Groothuis GM, Draaisma AL, Merema MT, Bezuijen JI, van Gils
MJ, Meijer DK, Friedman SL, Olinga P. 2005. Precision-cut liver slices as a new model
to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol
Sci 85:632-638.
80. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of mdr1a P-
glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone,
digoxin and cyclosporine A. J Clin Invest 96:1698-1705.
81. Adachi Y, Suzuki H, Schikel AH, Sugiyama Y. 2005. Role of breast cancer resistance
protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from ente-
rocytes to intestinal lumen. Mol Pharmacol 67:923-928.
82. Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. 2006.
Altered hepatobiliary disposition of 5 (and 6)-carboxy-2
,7
-dichlorofluorescein in
Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab Dispos 34:718-
723.
83. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa KI, Brouwer
KL. 2006. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excre-
tion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther
319:459-467.
84. Liu L, Pang KS. 2006. An integrated approach to model hepatic drug clearance. Eur J
Pharm Sci 29:215-230.
85. Sirianni GL, Pang KS. 1997. Organ clearance concepts: new perspectives on old princi-
ples. J Pharmacokinet Biopharm 25:449-470.
86. de Lannoy IA, Barker F 3rd, Pang KS. 1993. Formed and preformed metabolite excretion
clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat
in the single-pass and recirculating perfused rat liver. J Pharmacokinet Biopharm 21:
395-422.
87. Liu L, Pang KS. 2005. The roles of transporters and enzymes in hepatic drug processing.
Drug Metab Dispos 33:1-9.
88. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. 2006. Vectorial
transport of enalapril by rOatp1a1/rMrp2 and OATP1B1 and OATP1B3/MRP2 in rat and
human livers. J Pharmacol Exp Ther 318:395-402.
89. Liu L, Mak E, Tirona RG, Tan E, Novikoff PM, Wang P, Wolkoff AW, Pang KS. 2005.
Vascular binding, blood flow, transporter, and enzyme interactions on the processing of
digoxin in rat liver. J Pharmacol Exp Ther 315:433-448.
Search WWH ::
Custom Search